hi
Hi! How can I help you today?
i would like to know about gastritis /gerd
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive content from authoritative textbooks. Let me compose a thorough, well-organized response covering both conditions.
Gastritis & GERD — A Comprehensive Overview
PART 1: GASTRITIS
Definition
Gastritis is histologically documented inflammation of the gastric mucosa. It should not be confused with mucosal erythema seen on endoscopy, and is not interchangeable with "dyspepsia." When inflammatory cells are absent or rare, the more accurate term is gastropathy.
— Harrison's Principles of Internal Medicine 22E
Classification
| Category | Subtypes |
|---|---|
| Acute | H. pylori, phlegmonous/suppurative, emphysematous, other infectious |
| Chronic Atrophic | Type A (autoimmune, body-predominant) / Type B (H. pylori-related, antral-predominant) |
| Uncommon | Lymphocytic, eosinophilic, Crohn's disease, sarcoidosis, granulomatous |
Acute Gastritis
- Most common cause: Acute H. pylori infection — presents with sudden epigastric pain, nausea, vomiting, and marked neutrophilic infiltrate with edema and hyperemia
- If untreated, evolves into chronic gastritis; hypochlorhydria may follow for up to 1 year
- Phlegmonous (suppurative) gastritis: Rare, potentially life-threatening; involves the full gastric wall. Causative organisms include streptococci, staphylococci, E. coli, Proteus, and Haemophilus spp. May require gastrectomy if antibiotics fail
- Emphysematous gastritis: Caused by gas-producing organisms (C. perfringens, E. coli, S. aureus); gas seen in gastric wall and portal venous system on CT; can progress to gastric gangrene
Other causative agents: NSAIDs, alcohol, and any agent disrupting gastric mucosal protective mechanisms.
— Harrison's Principles of Internal Medicine 22E; Robbins Pathologic Basis of Disease; Sleisenger & Fordtran
Chronic Gastritis
Histologic stages (progressive):
- Superficial gastritis — inflammatory changes limited to the lamina propria; intact glands
- Atrophic gastritis — infiltrate extends deeper; progressive glandular distortion and destruction
- Gastric atrophy — glands lost; paucity of inflammatory infiltrate; mucosa thin with visible submucosal vessels
Intestinal metaplasia — conversion of gastric glands to small intestinal phenotype (goblet cells); occurs in all forms of chronic gastritis and is a significant risk factor for gastric adenocarcinoma
Type A vs Type B Chronic Gastritis
| Feature | Type A (Autoimmune) | Type B (H. pylori-related) |
|---|---|---|
| Location | Fundus/body (antral sparing) | Antrum-predominant |
| Mechanism | Autoimmune — anti-parietal cell & anti-intrinsic factor antibodies | H. pylori infection → antral inflammation |
| Acid production | Decreased (oxyntic gland destruction) | Initially increased |
| Key associations | Pernicious anemia, Vit. B12 deficiency, vitiligo, Addison's, thyroid disease | Peptic ulcer disease, gastric cancer |
| Antibodies | Anti-H⁺K⁺-ATPase (>90% pernicious anemia); Anti-IF antibodies (~40%) | Anti-H. pylori |
| HLA association | HLA-B8, HLA-DR3 | — |
Anti-parietal cell antibodies are present in up to 50% of Type A patients, ~20% of individuals >60 years, and ~20% of patients with vitiligo and Addison's disease.
— Harrison's Principles of Internal Medicine 22E
H. pylori Gastritis — Key Points
- Typically affects the antrum first, associated with increased gastric acid production and peptic ulcer disease
- As it progresses to pangastritis with body involvement, glandular atrophy leads to mildly reduced acid
- Induces MALT (mucosa-associated lymphoid tissue) — can give rise to B-cell MALTomas (MALT lymphomas)
- H. pylori eradication is the cornerstone of treatment — Robbins Pathologic Basis of Disease
Complications of Chronic Gastritis
| Complication | Mechanism |
|---|---|
| Peptic ulcer disease | H. pylori-induced hyperchlorhydria → mucosal injury |
| Gastric adenocarcinoma | Via intestinal metaplasia/dysplasia |
| MALToma | MALT induction by H. pylori |
| Pernicious anemia | Loss of intrinsic factor (Type A) → B12 malabsorption |
| Ménétrier disease | Excessive TGF-α → diffuse foveolar hyperplasia + protein-losing enteropathy |
| Zollinger-Ellison syndrome | Gastrin-secreting tumors → parietal cell hyperplasia + acid hypersecretion (60–90% malignant) |
PART 2: GERD (Gastroesophageal Reflux Disease)
Definition
GERD is a chronic disorder characterized by heartburn occurring when gastric acid or bile reflux passes from the stomach into the esophagus, inducing inflammation of the esophageal mucosa. Its prevalence has increased significantly over the past 20 years, in parallel with rising obesity rates.
— Yamada's Textbook of Gastroenterology
Pathophysiology & Risk Factors
The core mechanism is failure of the lower esophageal sphincter (LES) to prevent reflux:
- Increased transient LES relaxations — the main mechanism in most patients
- Reduced LES basal pressure — allows chronic acid exposure
- Obesity/abdominal obesity — increases intraabdominal pressure, reduces LES pressure, increases gastric acid production, reduces the intraabdominal length of the LES, and induces esophageal motor dysfunction
- BMI 25–29.9: OR for GERD = 1.43
- BMI >30: OR for GERD = 1.94
- Delayed gastric emptying — present in 20–30% of GERD patients
- Hiatal hernia — displaces the LES above the diaphragm, impairing its anti-reflux barrier
Symptoms
Typical (esophageal):
- Heartburn (pyrosis) — burning sensation rising from epigastrium to chest
- Acid regurgitation
- Water brash
Atypical / Extraesophageal:
- Chronic cough, laryngitis, hoarseness
- Non-cardiac chest pain
- Asthma exacerbations
- Dental enamel erosion — dissolution of enamel (especially palatal surfaces of maxillary teeth); teeth become temperature-sensitive; erosion is irreversible
- Early satiety, postprandial fullness, nausea (~30% of GERD patients also have functional dyspepsia)
Complications
| Complication | Notes |
|---|---|
| Erosive esophagitis | Mucosal breaks visible on endoscopy |
| Barrett's esophagus | Columnar metaplasia replacing squamous epithelium; OR = 4.0 with obesity |
| Esophageal adenocarcinoma | Risk increases with Barrett's; obesity OR = 2.1–2.4 |
| Esophageal stricture | From chronic fibrosis |
| Dental erosion | Irreversible enamel loss on palatal surfaces |
Diagnosis
- Clinical diagnosis in typical presentations (heartburn, regurgitation)
- Upper endoscopy (EGD) — for alarm symptoms, evaluation for Barrett's, erosive esophagitis
- Ambulatory pH monitoring — gold standard for confirming acid exposure
- Esophageal manometry — evaluates LES pressure and motility
Management
Step 1 — Lifestyle modifications:
- Weight loss (most effective single intervention)
- Elevate head of bed
- Avoid late-night meals, fatty foods, caffeine, alcohol, tobacco
- Avoid tight clothing
Step 2 — Pharmacologic therapy:
| Drug Class | Examples | Role |
|---|---|---|
| Proton Pump Inhibitors (PPIs) | Omeprazole, pantoprazole, lansoprazole | First-line; most effective for symptom control and healing esophagitis |
| H2-receptor antagonists | Ranitidine, famotidine | Milder disease; useful adjunct |
| Antacids | Calcium carbonate, magnesium hydroxide | Rapid but short-term relief |
| Prokinetics | Metoclopramide | Adjunct for delayed gastric emptying |
PPIs are the most effective medical therapy, including for dental erosion from GERD.
Step 3 — Surgical/procedural:
- Nissen fundoplication — gold standard surgical option; wraps gastric fundus around LES
- Radiofrequency ablation (Stretta procedure) — for patients who improve gastric emptying and normalize gastric electrical rhythms
- Reserved for those with confirmed GERD who fail or are intolerant of medical therapy
GERD & Overlap Syndromes
GERD frequently overlaps with:
- Functional dyspepsia (FD) — ~30% of GERD patients
- Gastroparesis — 20–30% of GERD patients
- IBS — GERD, gastroparesis, and IBS often coexist, reflecting diffuse GI neuromuscular dysfunction — Sleisenger & Fordtran's Gastrointestinal and Liver Disease
Quick Comparison Summary
| Feature | Gastritis | GERD |
|---|---|---|
| Primary site | Gastric mucosa | Esophageal mucosa (from acid reflux) |
| Key cause | H. pylori, NSAIDs, autoimmune | LES dysfunction, obesity |
| Main symptom | Epigastric pain, nausea, vomiting | Heartburn, regurgitation |
| Key investigation | Endoscopy + biopsy (histology) | pH monitoring, endoscopy |
| Main treatment | H. pylori eradication, PPI, avoid NSAIDs | PPIs, lifestyle changes, fundoplication |
| Major complication | Gastric cancer, pernicious anemia, MALToma | Barrett's esophagus, adenocarcinoma |
Sources: Harrison's Principles of Internal Medicine 22E | Robbins Pathologic Basis of Disease | Sleisenger & Fordtran's Gastrointestinal and Liver Disease | Yamada's Textbook of Gastroenterology
This is a shared conversation. Sign in to Orris to start your own chat.